BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FlowCardia, Inc. Announces Availability Of The Peripheral CROSSER(TM) Catheter Portfolio In Europe


1/25/2007 12:04:42 PM

SUNNYVALE, Calif., Jan. 25 /PRNewswire/ -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, announced availability of the CROSSER(TM) 14P, CROSSER(TM) 14S and CROSSER(TM) 18 CTO Recanalization Catheters in the European Union. The Peripheral CROSSER Catheters are designed to facilitate the placement of guidewires beyond vessel narrowing and CTOs in leg arteries.

The three peripheral CROSSER Catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to safely and quickly cross CTOs to help restore blood flow to the lower legs. The CROSSER Catheters are delivered using standard guidewires to the site of the occlusion in the legs. The CROSSER Catheters then utilize high-frequency vibration to facilitate guidewire crossing of the occlusion allowing for subsequent plaque debulking (removal), balloon angioplasty or stent placement. For many patients, this cath-lab based, minimally invasive approach to CTO recanalization can eliminate the need for potentially traumatic bypass graft surgery or leg amputation.

The CROSSER 14P, 14S and 18 Catheter European introduction follows the completion of over 380 coronary and peripheral CROSSER Catheter CTO cases throughout the US and Europe.

"The entire FlowCardia coronary and peripheral CROSSER Catheter portfolio is now available for European Union distribution," said Wick Goodspeed, President and CEO of FlowCardia. "We are very eager to offer the European interventionalists a significantly less invasive therapeutic option for their coronary and peripheral chronic total occlusion patients."

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture safe and effective, endovascular CTO recanalization systems. Additional information is available on the Company's new Web Site at http://www.flowcardia.com .

CONTACT: Mark Page Director, Marketing FlowCardia, Inc. 408-617-0352 ext. 301

FlowCardia, Inc.

CONTACT: Mark Page, Director, Marketing, FlowCardia, Inc.,+1-408-617-0352, ext.301



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES